

### Stem Cell Electroporation


The NEPA21 is the only device on the market to approach Stem Cell Electroporation from the perspective of optimising delivered energy.

- The finer control over the delivered energy available with the NEPA21 offers specific and important advantages for stem cell electroporation. As the thrust of NEPA21 protocols is to minimise delivered energy, this means that the targets are electroporated with less current (than competing device protocols).
- For particularly sensitive and delicate targets, identifying and only delivering the required energy (and no more) to porate the membrane is of utmost importance for their viability post electroporation.
- The success of the NEPA21 for cell electroporation is evident by the number of laboratories what have published with the NEPA21 system, and the quantum of client laboratory verified Viability % and Transfection Efficiency %.
- No special buffers required. Cost we electroporation can be as low as E3.50 per cuvette.
- The NEPA21 system is supported by a suite of over 250 different electrode configurations, which further enhance the applicability of the system and empower researchers with further experimental options and opportunities.

### APPLICATIONS


#### Transfection *RESULTS* in Client Labs

##### Human iPS Cells





3 days after electroporation

##### Human iPS Cells




2 days after electroporation




7 days after electroporation

GFP is still expressed in the iPS cell colonies after cell passaging.

*Mouse ES Cells*




Viability: 74%




Transfection Efficiency: 88%

*Mouse Neurospheres*




Viability: 90%



Transfection Efficiency: 75%

*Embryoid Body in Adherence from human iPS Cells*




Generation of Induced Pluripotent Stem Cells (iPSCs)

*Data of disease-specific iPSC Generation (disease: LQT)*


*Transfection of multiple episomal plasmids into B cells*



iPSC colony one month after electroporation. (5X objective)



Alkaline phosphatase stain (Left: 4X objective Right: 10X objective)



Good expressions of stem cell markers TRA1-60 and OCT4.

(left green: TRA1-60, right green: OCT4, blue: DAPI, red: Phalloidin)

Courtesy of Dr. Toshio Nakanishi laboratory, Department of Pediatric Cardiology, Tokyo Women's Medical University, Japan


Evaluation of CRISPR activity of human iPS cells with NEPA21 transfection

**A**


	NEPA21 poring pulse		Tested iPSC lines (% of GFP positive cells)		
	Voltage (V)	Pulse (ms)	201B7	404C2	DMD-iPSC
Condition 1	100	5	17.2%	40.6%	39.9%
Condition 2	125	5	20.2%	52.0%	64.4%
Condition 3	150	5	17.0%	37.1%	59.7%
Condition 4	175	5	17.0%	*60.6%	61.9%

\*: cell viability was low


**B**



**C**



**D**



A. Optimization of transfection conditions using the NEPA21 super electroporator (Nepa Gene Co., Ltd.) in human iPS cell lines. Voltage and pulse width of Poring Pulse were examined. EGFP expression plasmids were transfected and the percentage of positive cells was analyzed using the LSRFortessa Cell Analyzer (BD).

B. Schematic of transfection procedure.

- C. Cas9 expression vector pHL-EF1a-SphcCas9-iP-A (Addgene ID: 60599) and sgRNA expression vector pHL-H1-ccdB-mEF1a-RiH (Addgene ID: 60601) were electroporated into iPSC cells and then the endogenous dystrophin gene cleavage activity was evaluated by the T7E1 assay. The intensity of the cleaved bands (◀ red arrows) was detected with a TapeStation (Agilent) and the values are shown below the gel electrogram images.
- D. The same genomic DNA samples as in (C) were analyzed by RFLP with restriction enzyme XcmI (50-CCANNNNN^NNNTGG-30). The intensity of the uncut bands is indicated by ▶ red arrows. Because gRNA5 cleaves far from the XcmI site, no cleavage activity was detected in the RFLP assay.

Courtesy of Dr. HongMei Li and Dr. Akitsu Hotta, Center for iPSC Cell Research and Application (CiRA), Kyoto University

## STEM CELL

### Client Laboratory Verified RESULTS

*Transfection Data: iPSC Cells / ES Cells / Other Stem Cells*

See the cell images by clicking the cell names.

V: Viability, TE: Transfection Efficiency.

Cells name	V	TE	Cells name	V	TE
Human iPSC Cells (201B7)	86%	70%	Human iPSC Cells	94%	80%
<a href="#">Human iPSC Cells</a>			<a href="#">Human iPSC Cells</a>		
<a href="#">Human iPSC Cells (201B7)</a>	85%	94%	<a href="#">Human iPSC Cells (201B7)</a>		
Human iPSC Cells	69%	80%	<a href="#">Human iPSC Cells</a>		73%
<a href="#">Human iPSC Cells Derived Neural Cells</a>	93%	54%	<a href="#">Human ES Cells</a>		
<a href="#">Human ES Cells (H9 p.51)</a>	55%	55%	Human Mesenchymal Stem Cells	96.2 %	96.7 %
<a href="#">Human Mesenchymal Stem cells (Primary)</a>	78%	75%	<a href="#">Human Mesenchymal Stem Cells</a>	70%	80%
<a href="#">Human Neural Stem Cells</a>	97%	95%	Human Neural Stem Cells	80%	83%
Human Deciduous Teeth Stem Cells (SHED)	90%	92%	Human Nucleated Cells Including Hematopoietic Stem Cells (Before cell isolation)	73%	90%
Mouse iPSC Cells	70%	50%	<a href="#">Mouse ES Cells</a>	80%	75%
<a href="#">Mouse ES Cells</a>	80%	68%	<a href="#">Mouse ES Cells</a>	74%	88%
<a href="#">Mouse ES cells (129 strain, R1/E)</a>	80%	90%	<a href="#">Mouse ES Cells</a>	70%	100%
<a href="#">Mouse ES Cells</a>	80%	90%	<a href="#">Mouse iPSC cell derived Neural Stem Cells</a>		86%
<a href="#">Mouse Neural Stem Cells</a>	90%	80%	Mouse Neural Stem cells (Primary)	80%	60%
<a href="#">Mouse Neurospheres</a>	90%	75%	<a href="#">Mouse Neurospheres</a>		

<a href="#">Mouse Trophoblast Stem Cells</a>	59%	47%	<a href="#">C3H/10T1/2 Mouse Mesenchymal Stem Cells</a>	70%	85%
Mouse Mesenchymal Stem Cells	99%	89%	Mouse Hematopoietic Stem Cells (c-Kit positive cells)	66%	45%
Rat ES Cells	70%	76%	Rat ES Cells	60%	80%

For clients who have the NEPA21 system, we provide quite a lot of further know-how data for *IPS/ES/Other stem cells transfection* with high efficiency and high viability. Contact [sales@sonidel.com](mailto:sales@sonidel.com) for further information or to schedule a TRIAL.

## PUBLICATIONS

### IPS/ES/OTHER STEM CELLS

hESC	cyiPSC	Human dental pulp stem cells (DPSCs)
hESCs	bEDSCs	Human adipose mesenchymal stem cells (hAMSCs)
hiPSCs	ADSCs	Rat hair follicle stem cells
hiMSC	Neurosphere	Shrew permatogonial stem cells (SSCs)
Reprogramming of iPSCs	mESCs	
iPSCs		

#### hESC

##### **Perturbed cell fate decision by schizophrenia-associated AS3MTd2 isoform during corticogenesis**

Kim S, Woo Y, Um D, Chun I, Noh SJ, Ji HA, Jung N, Goo BS, Yoo JY, Mun DJ, Nghi TD, Nhung TTM, Han SH, Lee SB, Lee W, Yun J, So KH, Kim DK, Jang H, Suh Y, Rah JC, Baek ST, Yoon KJ, Kim MS, Kim TK, Park SK.

Sci Adv. 2025 Mar 28;11(13):eadp8271.

#### hESCs

##### **Longitudinal analysis of genetic and epigenetic changes in human pluripotent stem cells in the landscape of culture-induced abnormality**

Kim YJ, Kang B, Kweon S, Oh S, Kim D, Gil D, Lee H, Kim JH, Ju JH, Roh TY, Hong CP, Cha HJ.

Exp Mol Med. 2024 Nov 1.

##### **Temporal morphogen gradient-driven neural induction shapes single expanded neuroepithelium brain organoids with enhanced cortical identity**

Anna Pagliaro, Roxy Finger, Iris Zoutendijk, Saskia Bunschuh, Hans Clevers, Delilah Hendriks, Benedetta Artegiani

Nat Commun. 2023 Nov 28;14(1):7361.

##### **Toward Spatial Identities in Human Brain Organoids-on-Chip Induced by Morphogen-Soaked Beads**

Lihi Ben-Reuven, Orly Reiner

Bioengineering (Basel) . 2020 Dec 18;7(4):164.

##### **The Lineage-Specific Transcription Factor CDX2 Navigates Dynamic Chromatin to Control Distinct Stages of Intestine Development**

Kumar N, Tsai YH, Chen L, Zhou A, Banerjee KK, Saxena M, Huang S, Toke NH, Xing J, Shivdasani RA, Spence JR, Verzi MP.

Development. 2019 Mar 1;146(5): dev172189.

##### **Human Brain Organoids on a Chip Reveal the Physics of Folding**

Karzbrun E, Kshirsagar A, Cohen SR, Hanna JH, Reiner O

Nat Phys. 2018 May;14(5):515-522.

##### **Gene Manipulation of Human Embryonic Stem Cells by In Vitro-Synthesized mRNA for Gene Therapy**

Wang XL, Yu L, Ding Y, Guo XR, Yuan YH, Li DS

Curr Gene Ther. 2015;15(4):428-35.

#### hiPSCs

##### **Isolation and tracing of matrix-producing notochordal and chondrocyte cells using ACAN-2A-mScarlet reporter human iPSC lines**

Tong X, Poramba-Liyanage DW, van Hoolwerff M, Riemers FM, Montilla-Rojo J, Warin J, Salvatori D, Camus A, Meulenbelt I, Ramos YFM, Geijsen N, Tryfonidou MA, Shang P.

Sci Adv. 2024 Oct 25;10(43):eadp3170.

**Patient-derived and gene-edited pluripotent stem cells lacking NPHP1 recapitulate juvenile nephronophthisis in abnormalities of primary cilia and renal cyst formation**

Yutaka Arai, Hidenori Ito, Tomoya Shimizu, Yuzuno Shimoda, Dan Song, Mami Matsuo-Takasaki, Tadayoshi Hayata, Yohei Hayashi  
Front Cell Dev Biol . 2024 Jun 26;12:1370723.

**TAD boundary deletion causes PITX2-related cardiac electrical and structural defects**

Baudic M, Murata H, Bosada FM, Melo US, Aizawa T, Lindenbaum P, van der Maarel LE, Guedon A, Baron E, Fremy E, Foucal A, Ishikawa T, Ushinohama H, Jurgens SJ, Choi SH, Kyndt F, Le Scouarnec S, Wakker V, Thollet A, Rajalu A, Takaki T, Ohno S, Shimizu W, Horie M, Kimura T, Ellinor PT, Petit F, Dulac Y, Bru P, Boland A, Deleuze JF, Redon R, Le Marec H, Le Tourneau T, Gourraud JB, Yoshida Y, Makita N, Vieyres C, Makiyama T, Mundlos S, Christoffels VM, Probst V, Schott JJ, Barc J.  
Nat Commun. 2024 Apr 20;15(1):3380.

**CRISPR loss of function screening to identify genes involved in human primordial germ cell-like cell development**

Hwang YS, Seita Y, Blanco MA, Sasaki K.  
PLoS Genet. 2023 Dec 13;19(12):e1011080.

**Uniform transgene activation in Tet-On systems depends on sustained rtTA expression**

Otomo J, Woltjen K, Sakurai H.  
iScience. 2023 Aug 19;26(10):107685.

**Modelling renal defects in Bardet-Biedl syndrome patients using human iPSCs**

James Williams, Chloe Hurling, Sabrina Munir, Peter Harley, Carolina Barcellos Machado, Ana-Maria Cujba, Mario Alvarez-Fallas, Davide Danovi, Ivo Lieberam, Rocio Sancho, Philip Beales, Fiona M Watt  
Front Cell Dev Biol . 2023 Jun 2;11:1163825.

**Exocyst complex component 2 is a potential host factor for SARS-CoV-2 infection**

Yi R, Hashimoto R, Sakamoto A, Matsumura Y, Nagao M, Takahashi K, Takayama K.  
iScience. 2022 Nov 18;25(11):105427.

**A muscle fatigue-like contractile decline was recapitulated using skeletal myotubes from Duchenne muscular dystrophy patient-derived iPSCs**

Uchimura T, Asano T, Nakata T, Hotta A, Sakurai H.  
Cell Rep Med. 2021 Jun 4;2(6):100298.

**Core-shell hydrogel microfiber-expanded pluripotent stem cell-derived lung progenitors applicable to lung reconstruction in vivo**

Ikeo S, Yamamoto Y, Ikeda K, Sone N, Korogi Y, Tomiyama L, Matsumoto H, Hirai T, Hagiwara M, Gotoh S.  
Biomaterials. 2021 Sep;276:121031.

**Successful Correction of ALD Patient-derived iPSCs Using CRISPR/Cas9**

Eul Sik Jung, Zhejiu Quan, Mi-Yoon Chang, Wonjun Hong, Ji Hun Kim, Seung Hyun Kim, Seungkwon You, Dae-Sung Kim, Jiho Jang, Sang-Hun Lee, Hyongbum (Henry) Kim, Hoon Chul Kang  
bioRxiv February 25, 2020

**In vitro characterization of the human segmentation clock**

Margarete Diaz-Cuadros, Daniel E Wagner, Christoph Budjan, Alexis Hubaud, Oscar A Tarazona, Sophia Donnelly, Arthur Michaut, Ziad Al Tanoury, Kumiko Yoshioka-Kobayashi, Yusuke Niino, Ryoichiro Kageyama, Atsushi Miyawaki, Jonathan Touboul, Olivier Pourquié  
Nature. 2020 Apr;580(7801):113-118.

**Functional Evaluation of the Pathological Significance of MEFV Variants Using Induced Pluripotent Stem Cell-Derived Macrophages**

Shiba T, Tanaka T, Ida H, Watanabe M, Nakaseko H, Osawa M, Shibata H, Izawa K, Yasumi T, Kawasaki Y, Saito MK, Takita J, Heike T, Nishikomori R.  
J Allergy Clin Immunol. 2019 Nov;144(5):1438-1441.e12.

**Persistent Epigenetic Memory Impedes Rescue of the Telomeric Phenotype in Human ICF iPSCs Following DNMT3B Correction**

Toubiana S, Gagliardi M, Papa M, Manco R, Tzukerman M, Matarazzo MR, Selig S.  
Elife. 2019 Nov 20;8:e47859.

**Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies**

Kawai K, Negoro R, Ichikawa M, Yamashita T, Deguchi S, Harada K, Hirata K, Takayama K, Mizuguchi H.  
Mol Ther Methods Clin Dev. 2019 Nov 21;17:49-57

**A Versatile Toolbox for Knock-In Gene Targeting Based on the Multisite Gateway Technology**

Yoshimatsu S, Sone T, Nakajima M, Sato T, Okochi R, Ishikawa M, Nakamura M, Sasaki E, Shiozawa S, Okano H.  
PLoS One. 2019 Aug 27;14(8):e0221164.

**Core Transcription Factors Promote Induction of PAX3-Positive Skeletal Muscle Stem Cells**

Sato T, Higashioka K, Sakurai H, Yamamoto T, Goshima N, Ueno M, Sotozono C.  
Stem Cell Reports. 2019 Aug 13;13(2):352-365.

#### **Phenotype-Based High-Throughput Classification of Long QT Syndrome Subtypes Using Human Induced Pluripotent Stem Cells**

Yoshinaga D, Baba S, Makiyama T, Shibata H, Hirata T, Akagi K, Matsuda K, Kohjitani H, Wuriyanghai Y, Umeda K, Yamamoto Y, Conklin BR, Horie M, Takita J, Heike T.  
Stem Cell Reports. 2019 Aug 13;13(2):394-404.

#### **Aberrant Axon Branching via Fos-B Dysregulation in FUS-ALS Motor Neurons**

Akiyama T, Suzuki N, Ishikawa M, Fujimori K, Sone T, Kawada J, Funayama R, Fujishima F, Mitsuzawa S, Ikeda K, Ono H, Shijo T, Osana S, Shirota M, Nakagawa T, Kitajima Y, Nishiyama A, Izumi R, Morimoto S, Okada Y, Kamei T, Nishida M, Nogami M, Kaneda S, Ikeuchi Y, Mitsuhashi H, Nakayama K, Fujii T, Warita H, Okano H, Aoki M.  
EBioMedicine. 2019 Jul;45:362-378.

#### **Genome-wide Microhomologies Enable Precise Template-Free Editing of Biologically Relevant Deletion Mutations**

Grajcarek J, Monlong J, Nishinaka-Arai Y, Nakamura M, Nagai M, Matsuo S, Loughheed D, Sakurai H, Saito MK, Bourque G, Woltjen K.  
Nat Commun. 2019 Oct 24;10(1):4856.

#### **Function and Immunogenicity of Gene-corrected iPSC-derived Hepatocyte-Like Cells in Restoring Low Density Lipoprotein Uptake in Homozygous Familial Hypercholesterolemia.**

Okada H, Nakanishi C, Yoshida S, Shimojima M, Yokawa J, Mori M, Tada H, Yoshimuta T, Hayashi K, Yamano T, Hanayama R, Yamagishi M, Kawashiri MA  
Sci Rep. 2019 Mar 18;9(1):4695.

#### **Verification and rectification of cell type-specific splicing of a Seckel syndrome-associated ATR mutation using iPSC cell model.**

Ichisima J, Suzuki NM, Samata B, Awaya T, Takahashi J, Hagiwara M, Nakahata T, Saito MK.  
J Hum Genet. 2019 May;64(5):445-458.

#### **MiR-33a is a therapeutic target in SPG4-related hereditary spastic paraplegia human neurons**

Nakazeki F, Tsuge I, Horie T, Imamura K, Tsukita K, Hotta A, Baba O, Kuwabara Y, Nishino T, Nakao T, Nishiga M, Nishi H, Nakashima Y, Ide Y, Koyama S, Kimura M, Tsuji S, Naitoh M, Suzuki S, Izumi Y, Kawarai T, Kaji R, Kimura T, Inoue H, Ono K  
Clin Sci (Lond). 2019 Feb 22;133(4):583-595.

#### **Increased Cytotoxicity of Herpes Simplex Virus Thymidine Kinase Expression in Human Induced Pluripotent Stem Cells**

Iwasawa C, Tamura R, Sugiura Y, Suzuki S, Kuzumaki N, Narita M, Suematsu M, Nakamura M, Yoshida K, Toda M, Okano H, Miyoshi H.  
Int J Mol Sci. 2019 Feb 14;20(4):810.

#### **A Patient-Derived iPSC Model Revealed Oxidative Stress Increases Facioscapulohumeral Muscular Dystrophy-Causative DUX4**

Sasaki-Honda M, Jonouchi T, Arai M, Hotta A, Mitsuhashi S, Nishino I, Matsuda R, Sakurai H.  
Hum Mol Genet. 2018 Dec 1;27(23):4024-4035.

#### **Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy**

Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.  
Cell Stem Cell. 2018 Dec 6;23(6):850-858.e4.

#### **Organoids from Nephrotic Disease-Derived iPSCs Identify Impaired NEPHRIN Localization and Slit Diaphragm Formation in Kidney Podocytes**

Tanigawa S, Islam M, Sharmin S, Naganuma H, Yoshimura Y, Haque F, Era T, Nakazato H, Nakanishi K, Sakuma T, Yamamoto T, Kurihara H, Taguchi A, Nishinakamura R  
Stem Cell Reports. 2018 Sep 11;11(3):727-740.

#### **Generation of D1-1 TALEN isogenic control cell line from Dravet syndrome patient iPSCs using TALEN-mediated editing of the SCN1A gene.**

Tanaka Y, Sone T, Higurashi N, Sakuma T, Suzuki S, Ishikawa M, Yamamoto T, Mitsui J, Tsuji H, Okano H, Hirose S  
Stem Cell Res. 2018 Apr;28:100-104.

#### **Microhomology-assisted Scarless Genome Editing in Human iPSCs**

Kim SI, Matsumoto T, Kagawa H, Nakamura M, Hirohata R, Ueno A, Ohishi M, Sakuma T, Soga T, Yamamoto T, Woltjen K.  
Nat Commun. 2018 Mar 5;9(1):939.

#### **Down-regulation of Ghrelin Receptors on Dopaminergic Neurons in the Substantia Nigra Contributes to Parkinson's Disease-Like Motor Dysfunction**

Suda Y, Kuzumaki N, Sone T, Narita M, Tanaka K, Hamada Y, Iwasawa C, Shibasaki M, Maekawa A, Matsuo M, Akamatsu W, Hattori N, Okano H, Narita M.  
Mol Brain, 11 (1), 6 2018 Feb 20

**Pluripotent stem cell models of Blau syndrome reveal an IFN- $\gamma$ -dependent inflammatory response in macrophages.**

Takada S, Kambe N, Kawasaki Y, Niwa A, Honda-Ozaki F, Kobayashi K, Osawa M, Nagahashi A, Semi K, Hotta A, Asaka I, Yamada Y, Nishikomori R, Heike T, Matsue H, Nakahata T, Saito MK  
J Allergy Clin Immunol. 2018 Jan;141(1):339-349.e11.

**Site-specific Randomization of the Endogenous Genome by a Regulatable CRISPR-Cas9 piggyBac System in Human Cells**

Ishida K, Xu H, Sasakawa N, Lung MSY, Kudryashev JA, Gee P, Hotta A.  
Sci Rep. 2018 Jan 10;8(1):310.

**A human iPS cell myogenic differentiation system permitting high-throughput drug screening**

Uchimura T, Otomo J, Sato M, Sakurai H.  
Stem Cell Res. 2017 Dec;25:98-106.

**CRISPR Correction of a Homozygous Low-Density Lipoprotein Receptor Mutation in Familial Hypercholesterolemia Induced Pluripotent Stem Cells**

Omer L, Hudson EA, Zheng S, Hoying JB, Shan Y, Boyd NL.  
Hepatol Commun. 2017 Nov;1(9):886-898.

**Impairment of the transition from proliferative stage to prehypertrophic stage in chondrogenic differentiation of human induced pluripotent stem cells harboring the causative mutation of achondroplasia in fibroblast growth factor receptor 3**

Horie N, Hikita A, Nishizawa S, Uto S, Takato T, Hoshi K.  
Regen Ther. 2017 Jan 26;6:15-20.

**Myogenic Differentiation from MYOGENIN-Mutated Human iPS Cells by CRISPR/Cas9.**

Higashioka K, Koizumi N, Sakurai H, Sotozono C, Sato T  
Stem Cells Int. 2017;2017:9210494.

**CRISPR/Cas9 Genome Editing to Repair Receptor-Mediated Endocytosis in Homozygous Familial Hypercholesterolemia Induced Pluripotent Stem Cells**

Linda Omer, Elizabeth A Hudson, Jay B Hoying, Nolan L Boyd  
The FASEB Journal Vol. 31, 909.2, 1 Apr 2017

**Proteasome Impairment in Neural Cells Derived From HMSN-P Patient iPSCs**

Murakami N, Imamura K, Izumi Y, Egawa N, Tsukita K, Enami T, Yamamoto T, Kawarai T, Kaji R, Inoue H.  
Mol Brain, 10 (1), 7 2017 Feb 15

**Cochlear Cell Modeling Using Disease-Specific iPSCs Unveils a Degenerative Phenotype and Suggests Treatments for Congenital Progressive Hearing Loss.**

Hosoya M, Fujioka M, Sone T, Okamoto S, Akamatsu W, Ukai H, Ueda HR, Ogawa K, Matsunaga T, Okano H  
Cell Rep. 2017 Jan 3;18(1):68-81.

**Genetic and Pharmacological Correction of Aberrant Dopamine Synthesis Using Patient iPSCs With BH4 Metabolism Disorders**

Ishikawa T, Imamura K, Kondo T, Koshiba Y, Hara S, Ichinose H, Furujo M, Kinoshita M, Oeda T, Takahashi J, Takahashi R, Inoue H.  
Hum Mol Genet. 2016 Dec 1;25(23):5188-5197.

**Calcium Dysregulation Contributes to Neurodegeneration in FTLD Patient iPSC-derived Neurons**

Imamura K, Sahara N, Kanaan NM, Tsukita K, Kondo T, Kutoku Y, Ohsawa Y, Sunada Y, Kawakami K, Hotta A, Yawata S, Watanabe D, Hasegawa M, Trojanowski JQ, Lee VM, Suhara T, Higuchi M, Inoue H  
Sci Rep. 2016 Oct 10;6:34904.

**Human Induced Pluripotent Stem Cell-Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation**

Sharmin S, Taguchi A, Kaku Y, Yoshimura Y, Ohmori T, Sakuma T, Mukoyama M, Yamamoto T, Kurihara H, Nishinakamura R.  
J Am Soc Nephrol. 2016 Jun;27(6):1778-91.

**Inducible Transgene Expression in Human iPS Cells Using Versatile All-in-One piggyBac Transposons.**

Kim SI, Ocegüera-Yanez F, Sakurai C, Nakagawa M, Yamanaka S, Woltjen K  
Methods Mol Biol. 2016;1357:111-31.

**Sall1 transiently marks undifferentiated heart precursors and regulates their fate.**

Morita Y, Andersen P, Hotta A, Tsukahara Y, Sasagawa N, Hayashida N, Koga C, Nishikawa M, Saga Y, Evans SM, Koshiba-Takeuchi K, Nishinakamura R, Yoshida Y, Kwon C, Takeuchi JK  
J Mol Cell Cardiol. 2016 Mar;92:158-62.

**Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system.**

Li HL, Gee P, Ishida K, Hotta A  
Methods. 2015 Oct 23. pii: S1046-2023(15)30133-X.

**Targeted Gene Correction of RUNX1 in Induced Pluripotent Stem Cells Derived From Familial Platelet Disorder With Propensity to Myeloid Malignancy Restores Normal Megakaryopoiesis**

Iizuka H, Kagoya Y, Kataoka K, Yoshimi A, Miyauchi M, Taoka K, Kumano K, Yamamoto T, Hotta A, Arai S, Kurokawa M.  
Exp Hematol. 2015 Oct;43(10):849-57.

**Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells**

Shoji E, Sakurai H, Nishino T, Nakahata T, Heike T, Awaya T, Fujii N, Manabe Y, Matsuo M, Sebara-Fujisawa A.  
Sci Rep. 2015 Aug 20;5:12831.

**Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9**

Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H, Yamamoto T, Yamanaka S, Hotta A.  
Stem Cell Reports. 2015 Jan 13;4(1):143-154.

**hiPSCs  
hiMSC**

**Panel of human cell lines with human/mouse artificial chromosomes**

Uno N, Takata S, Komoto S, Miyamoto H, Nakayama Y, Osaki M, Mayuzumi R, Miyazaki N, Hando C, Abe S, Sakuma T, Yamamoto T, Suzuki T, Nakajima Y, Oshimura M, Tomizuka K, Kazuki Y.  
Sci Rep. 2022 Feb 22;12(1):3009.

**hiPSCs  
Reprogramming\_of\_iPSCs**

**Establishment of a Non-Integrate iPSC Cell Line CSUASOi002-A, From Urine-Derived Cells of a Female Patient With Macular Corneal Dystrophy Carrying Compound Heterozygous CHST6 Mutations**

Jing Y, Zhou Y, Wang C, Liu J, Guo Y, Mao S, Chan HF, Tang S, Chen J.  
Stem Cell Res. 2019 Dec;41:101598.

**iPSCs**

**Cryptotanshinone is a candidate therapeutic agent for interstitial lung disease associated with a BRICHOS-domain mutation of SFTPC**

Hosokawa M, Mikawa R, Hagiwara A, Okuno Y, Awaya T, Yamamoto Y, Takahashi S, Yamaki H, Osawa M, Setoguchi Y, Saito MK, Abe S, Hirai T, Gotoh S, Hagiwara M.  
iScience. 2023 Aug 25;26(10):107731.

**cyiPSC**

**Generation of Monkey Induced Pluripotent Stem Cell-Derived Cartilage Lacking Major Histocompatibility Complex Class I Molecules on the Cell Surface**

Okutani Y, Abe K, Yamashita A, Morioka M, Matsuda S, Tsumaki N.  
Tissue Eng Part A. 2022 Jan;28(1-2):94-106.

**bEDSCs**

**Pluripotent stem cells related to embryonic disc exhibit common self-renewal requirements in diverse livestock species**

Kinoshita M, Kobayashi T, Planells B, Klisch D, Spindlow D, Masaki H, Bornelöv S, Stirparo GG, Matsunari H, Uchikura A, Lamas-Toranzo I, Nichols J, Nakauchi H, Nagashima H, Alberio R, Smith A.  
Development. 2021 Dec 1;148(23):dev199901.

**ADSCs**

**The Transplantation Resistance of Type II Diabetes Mellitus Adipose-Derived Stem Cells Is Due to G6PC and IGF1 Genes Related to the FoxO Signaling Pathway**

Horiguchi M, Turudome Y, Ushijima K.  
Int J Mol Sci. 2021 Jun 19;22(12):6595.

**Neurosphere**

**Heterogeneous nuclear ribonucleoprotein U (HNRNPU) safeguards the developing mouse cortex**

Sapir T, Kshirsagar A, Gorelik A, Olender T, Porat Z, Scheffer IE, Goldstein DB, Devinsky O, Reiner O.  
Nat Commun. 2022 Jul 21;13(1):4209.

**mESCs**

**Developmental Analyses of Mouse Embryos and Adults Using a Non-Overlapping Tracing System for All Three Germ Layers**

Serizawa T, Isotani A, Matsumura T, Nakanishi K, Nonaka S, Shibata S, Ikawa M, Okano H.  
Development. 146 (21) 2019 Nov 4

**Preparation and electroporation of Cas12a/Cpf1-guide RNA complexes for introducing large gene deletions in mouse embryonic stem cells**

Kissling L, Monfort A, Swarts DC, Wutz A, Jinek M  
Methods Enzymol. 2019;616:241-263.

**Human\_dental\_pulp\_stem\_cells (DPSCs)**

**Novel Gain-Of-Function Mutation of TRPV4 Associated With Accelerated Chondrogenic Differentiation of Dental Pulp Stem Cells Derived From a Patient With Metatropic Dysplasia**

Nonaka K, Han X, Kato H, Sato H, Yamaza H, Hirofuji Y, Masuda K.  
Biochem Biophys Rep. 2019 May 17:19:100648.

**Human adipose mesenchymal stem cells (hAMSCs)**

**CRISPR/Cas9-Mediated Knockin Application in Cell Therapy: A Non-viral Procedure for Bystander Treatment of Glioma in Mice.**

Meca-Cortés O, Guerra-Rebollo M, Garrido C, Borrós S, Rubio N, Blanco J  
Mol Ther Nucleic Acids. 2017 Sep 15:8:395-403.

**Rat\_hair\_follicle\_stem\_cells**

**miR-339-5p negatively regulates loureirin A-induced hair follicle stem cell differentiation by targeting DLX5.**

Li X, Wu Y, Xie F, Zhang F, Zhang S, Zhou J, Chen D, Liu A  
Mol Med Rep. 2018 Aug;18(2):1279-1286.

**Shrew spermatogonial stem cells (SSCs)**

**Long-term Propagation of Tree Shrew Spermatogonial Stem Cells in Culture and Successful Generation of Transgenic Offspring**

Li CH, Yan LZ, Ban WZ, Tu Q, Wu Y, Wang L, Bi R, Ji S, Ma YH, Nie WH, Lv LB, Yao YG, Zhao XD, Zheng P.  
Cell Res. 2017 Feb;27(2):241-252.